The remedy panorama for sufferers who expertise development after preliminary remedy for smooth tissue sarcomas continues to evolve, in accordance with Dr. Vinayak Venkataraman, medical oncologist.
Venkataraman sat down with CURE to debate rising second- and third-line therapeutic methods and investigational brokers that will shift the usual of take care of sufferers with the uncommon sarcoma often called gastrointestinal stromal tumors (GIST).
He at the moment serves because the director of Sarcoma Pathways and is a doctor at Dana-Farber Most cancers Institute, in Boston, Massachusetts, the place can also be an teacher in drugs and an affiliated college on the McGraw/Patterson Heart for Inhabitants Sciences, Harvard Medical College.
Transcript
Are you able to talk about rising second- and third-line remedy approaches in growth for sufferers who’ve progressed after preliminary remedy, and which investigational brokers or mixtures you consider present probably the most promise at the moment?
There’s one other novel compound referred to as IDRX-42 which was examined in a closely pretreated inhabitants, together with within the second line, the place it had a really encouraging goal response price in that closely pretreated inhabitants and virtually a 50% response price within the second line. That was introduced at our Connective Tissue Oncology Society assembly final yr in San Diego, and primarily based on these outcomes of how properly sufferers had been doing on the second line, we will be half of a giant multicenter trial Sutent (sunitinib) versus IDRX-42 in that second-line inhabitants.
Once more, these are two potential novel compounds or novel mixtures that would doubtlessly change our customary of care within the second and third line of remedy. So these are those we’re most enthusiastic about.
Moreover, there are some part 1 trials trying on the mixture of Gleevec (imatinib) and a menin inhibitor, as a result of biologically within the lab, there’s been some synergy seen in sufferers who’ve progressed on Gleevec by itself. Moreover, then are some pan-KIT inhibitors popping out which can be additionally in medical trial.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training,
